McKesson Corporation (MCK) - Stock Analysis
Last updated: Jan 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
McKesson shows strong short-term momentum with a 10% revenue increase and earnings beat in Q2 FY2026, supported by strategic specialty pharma growth and positive analyst upgrades (Zacks Strong Buy). Technicals confirm ~11.6% gain over 21 days, well above key moving averages, indicating near-term price appreciation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Thin margins ⢠Strong FCF ⢠Negative equity McKesson is a very large, highâturnover distributor generating strong free cash flow but operating with razorâthin margins, negative book equity, a subâ1 current ratio and rising net debt, so its investment case hinges on sustained cash generation despite clear balanceâsheet vulnerabilities.
Price Behavior
Key Price Behavior Insights: ⢠Sideways consolidation ⢠Support holding ⢠Resistance capped Support Level: $800 Resistance Level: $830â$835 Over the last month MCK has been consolidating after retreating from ~ $880 to about $825, trading sideways with solid support near $800 but capped by resistance around $830â$835.
Sentiment & News
Key News Insights: ⢠Revenue growth ⢠Margin expansion ⢠Institutional buying McKesson is showing strong revenue and margin expansion from its oncology/multispecialty pivot and divestitures, drawing increased institutional buying and positive analyst sentiment that underpin continued earnings momentum into 2026.
AI Summary
McKesson's strategic pivot into higherâmargin specialty distribution (oncology, GLPâ1, automation) has transformed it into a cashâflow generator with real upside if execution continues, but investors must treat nearâterm upside as contingent on stabilizing liquidity and workingâcapital dynamics â specifically rising cash, declining net debt, a current ratio >1, and no further large receivable/badâdebt shocks. Monitor quarterly specialty volumes/margins, cash conversion and payables behavior closely; breach of support ~800 or any repeat receivable hit should trigger reassessment or de-risking.
Description
McKesson Corporation is a healthcare services and distribution company operating in the United States and select international markets. Its operations span pharmaceutical distribution, medical-surgical supply logistics, and a range of technology, consulting and outsourcing services for pharmacies, specialty practices and institutional customers, while a dedicated business supports biopharma partners and supply-chain needs. The company was founded in 1833 and is headquartered in Irving, Texas.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 10 | Nov 17 | MCK | McKesson Corporation | McKesson shows strong short-term momentum with a 10% revenue increase and earnings beat in Q2 FY2026, supported by strategic specialty pharma growth and positive analyst upgrades (Zacks Strong Buy). Technicals confirm ~11.6% gain over 21 days, well above key moving averages, indicating near-term price appreciation potential. | Closed | -0.5% |